Establishment Labs Q4 revenue beats on strong demand

Overview

• Medical technology firm's Q4 revenue rose 45%, beating analyst expectations

• Adjusted EPS for Q4 beat analyst expectations

• Net income for Q4 exceeded analyst estimates

Outlook

• Establishment Labs projects 2026 revenue between $264 mln and $266 mln

• Company expects 2027 revenue growth to be at least 25%

• Establishment Labs anticipates positive cash flow in 2026 and 2027

Result Drivers

• MINIMALLY INVASIVE TECHNOLOGY - Preservé technology drove market expansion and increased demand, appealing to new consumer groups, per CEO Peter Caldini

• FINANCIAL DISCIPLINE - Co achieved positive adjusted EBITDA and reduced net loss significantly, showing improved financial discipline

• STRONG DEMAND - Continued strong demand from surgeons and patients contributed to revenue growth, according to CEO Peter Caldini

Company press release: ID:nBwlrm6xa

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Establishment Labs Holdings Inc is $84.50, about 12.7% above its February 23 closing price of $74.96

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.